What is OS Therapies's current debt?

OS Therapies (OSTX) reported current debt of $20M in Q1 2026.

What does current debt mean?

The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.

ImmunityBio, Inc.IBRX

——

Operating income-$10.2M-103%

Net income-$10.4M-168%

EPS (diluted)-$0.27-50.0%

Cash & equivalents$917.6K-69.1%

Total debt$20.0M—

Total equity-$10.8M-159%

Total assets$7.3M+71.7%

Operating cash flow-$4.6M-32.6%

CapEx$316.4K—

Free cash flow-$3.7M—

Market cap$84.62M+66.4%

Enterprise value$103.7M—

Return on equity470%—

Debt / equity-1.8×—

Current ratio0.1×-1.1×

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is OS Therapies's current debt?: OS Therapies (OSTX) reported current debt of $20M in Q1 2026.
What does current debt mean?: The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.